EFFECTS OF PRAVASTATIN AND CHOLESTYRAMINE ON CIRCULATING LEVELS OF PARATHYROID-HORMONE AND VITAMIN-D METABOLITES

Authors:
  • CCCN CORDER
    CN CORDER
  • SES EPSTEIN
    S EPSTEIN
  • GBG BARBI
    G BARBI
  • STS THOMAS
    S THOMAS

  • 1 September 1990
    • journal article
    • research article
    • Vol. 12  (5) , 427-430
    • PMID:2125243
Abstract
The subjects were 40 hypercholesterolemic patients (mean age, 58 years) receiving a low-fat diet and randomly assigned to treatment with placebo for eight weeks or 40 or 80 mg of pravastatin, 24 gm of cholestyramine, or 40 mg of pravastatin plus 24 gm of cholestyramine, or 40 mg of pravastatin plus 24 gm of cholestryamine daily for 24 weeks. After eight weeks of active treatment, levels of total and low-density lipoprotein cholesterol were significantly reduced and the decline was maintained for the remaining 16 weeks. Parathyroid hormone levels and levels of the vitamin D metabolites 1,25(OH)2D3 and 25(OH)D3 did not change during treatment. The results indicate that 24 weeks of treatment with pravastatin and cholestyramine does not affect calcium metabolism.